Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions

摘要: Adverse drug reactions (ADRs) have a major impact on patients, physicians, health care providers, regulatory agencies and pharmaceutical companies. Identifying the genetic contributions to ADR risk may lead better understanding of underlying mechanisms, identification patients at decrease in number events. Technological advances made routine monitoring investigation basis ADRs during clinical trials possible. We demonstrate through simulation that genome-wide genotyping, coupled with use clinically matched or population controls, can yield sufficient statistical power permit strong predictors prospective manner modest numbers cases. The results 500 000 single nucleotide polymorphism analysis abacavir-associated hypersensitivity reaction suggest known HLA-B gene region could be identified as few 15 cases 200 controls sequential analysis.